Clinical Study
The Effect of Fluoxetine on Progression in Progressive Multiple Sclerosis: A Double-Blind, Randomized, Placebo-Controlled Trial
Table 1
Baseline characteristics.
| | | Fluoxetine | Placebo | value |
| | Number | 20 | 22 | | | Disease course (SPMS/PPMS) | 14/6 | 15/7 | 0.90 | | Gender (male/Female) | 12/8 | 12/10 | 0.72 | | Age (years; mean, sd) | 49.7 (9.2) | 47.5 (7.6) | 0.42 | | Disease duration (years; mean, sd) | 14.8 (9.0) | 13.0 (6.2) | 0.45 | | EDSS (median, IQR) | 6.0 (5.0–6.5) | 5.75 (4.0–6.5) | 0.90 | | MSFC (mean, sd) | −0.29 (0.84) | −0.33 (0.44) | 0.87 | | 9HPT, sec (mean, sd) | 36 (33) | 30 (10) | 0.36 | | AI (median, IQR) | 3.5 (2.0–4.75) | 2.0 (2.0–5.0) | 0.47 | | FIS | 42 (29) | 44 (32) | 0.82 | | GNDS | 12 (7) | 11 (4) | 0.53 | | BDI | 9 (7) | 10 (6) | 0.50 | | T2LL (ml; mean, sd) | 7.8 (8.8) | 9.9 (9.1) | 0.47 | | WM volume (ml; mean, sd) | 624.5 (51.8) | 636.4 (56.2) | 0.48 | | GM volume (ml; mean, sd) | 622.6 (58.9) | 632.4 (57.9) | 0.59 |
|
|
EDSS: Expanded Disability Status Scale; MSFC: Multiple Sclerosis Functional Composite; 9HPT: 9-hole peg test; AI: ambulation index; FIS: Fatigue Impact Scale; GDNS: Guy’s Neurological Disability Scale; BDI: Beck’s Depression Inventory II; T2LL: T2 lesion load; WM: White Matter; GM: Grey Matter.
|
